
2 Biotech Stock to Buy Over Moderna This December
Published on December 22, 2022
Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA's growth,...
